- Home
- TC vs RLYB Comparison
TC vs RLYB Comparison
Compare TC & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TC | RLYB |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 28.7M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TC | RLYB |
|---|---|---|
| Price | $10.30 | $9.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.7K | ★ 247.3K |
| Earning Date | 03-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $0.46 | $0.22 |
| 52 Week High | $19.99 | $11.49 |
Technical Indicators
Market Signals| Indicator | TC | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 34.29 | 66.36 |
| Support Level | $8.93 | $0.48 |
| Resistance Level | $11.00 | $11.49 |
| Average True Range (ATR) | 0.56 | 0.86 |
| MACD | -0.12 | -0.32 |
| Stochastic Oscillator | 6.95 | 14.83 |
Price Performance
Historical ComparisonAbout TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.